在患有神经脊髓炎光谱障碍 (NMOSD) 的患者中,从抗间流-6单克隆抗体转换为拉武利祖马布后,尿路感染的减少:病例报告
Seiya Takahashi1, Taro Yasumoto1, Akinori Futamura1
1Neurology, Showa Medical University, Yokohama, JPN.
Cureus
|October 24, 2025
概括
萨特拉利祖马布 (Satralizumab) 是一种针对神经髓炎光学谱系障碍 (NMOSD) 的抗干细胞素-6疗法,可能会增加复发性尿路感染 (UTI) 的风险. 在一项案例研究中,切换到拉武利祖马布可以将尿路感染发病率减半,这表明对NMOSD患者进行仔细监测.
科学领域:
- 免疫学 免疫学 免疫学
- 神经学 神经学
- 传染性疾病 传染性疾病
背景情况:
- 神经脊髓炎光学谱系障碍 (NMOSD) 是一种严重的自身免疫性疾病.
- 生物疗法,包括抗干白素-6 (IL-6) 药物,用于NMOSD管理.
- 感染,如尿路感染 (UTI),可以在免疫治疗期间造成严重的并发症.
研究的目的:
- 报告NMOSD患者中发生的复发性尿路感染病例,患者接受了萨特拉利祖马布治疗.
- 调查抗IL-6疗法与复发性尿路感染之间的潜在关联.
- 突出监测和替代治疗考虑的必要性.
主要方法:
- 一个65岁的妇女患有抗水素4抗体阳性NMOSD的病例报告.
- 从萨特拉利祖马布转换为拉夫利祖马布之前和之后的尿路感染发病率分析.
- 监测临床参数,包括普得尼索隆剂量,HbA1c和尿液葡萄糖.
主要成果:
- 患者在开始萨特拉利祖马布治疗后出现了复发性尿路感染.
- 转换为ravulizumab导致尿路感染发病率减少了50%.
- 在普得尼索隆剂量,HbA1c或尿液葡萄糖水平上没有发现显著变化.
结论:
- 在NMOSD患者中,萨特拉利祖马布治疗可能与反复性尿路感染的敏感性增加有关.
- 临床医生应考虑在接受抗IL-6治疗的患者中监测尿路感染.
- 对于持久性感染,可以考虑使用C5补充抑制剂等替代治疗方法.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
01:17Urinary Tract Infection IV: Nursing Management
432
In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
432
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
308
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
308
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
250
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
250
01:30Urinary Tract Calculi III: Medical Management
193
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
193
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484